Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Medicinas Tradicionales
Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Am J Hum Genet ; 108(3): 517-524, 2021 03 04.
Artículo en Inglés | MEDLINE | ID: mdl-33667394

RESUMEN

Tuberculosis (TB), usually caused by Mycobacterium tuberculosis bacteria, is the first cause of death from an infectious disease at the worldwide scale, yet the mode and tempo of TB pressure on humans remain unknown. The recent discovery that homozygotes for the P1104A polymorphism of TYK2 are at higher risk to develop clinical forms of TB provided the first evidence of a common, monogenic predisposition to TB, offering a unique opportunity to inform on human co-evolution with a deadly pathogen. Here, we investigate the history of human exposure to TB by determining the evolutionary trajectory of the TYK2 P1104A variant in Europe, where TB is considered to be the deadliest documented infectious disease. Leveraging a large dataset of 1,013 ancient human genomes and using an approximate Bayesian computation approach, we find that the P1104A variant originated in the common ancestors of West Eurasians ∼30,000 years ago. Furthermore, we show that, following large-scale population movements of Anatolian Neolithic farmers and Eurasian steppe herders into Europe, P1104A has markedly fluctuated in frequency over the last 10,000 years of European history, with a dramatic decrease in frequency after the Bronze Age. Our analyses indicate that such a frequency drop is attributable to strong negative selection starting ∼2,000 years ago, with a relative fitness reduction on homozygotes of 20%, among the highest in the human genome. Together, our results provide genetic evidence that TB has imposed a heavy burden on European health over the last two millennia.


Asunto(s)
ADN Antiguo/análisis , Polimorfismo Genético/genética , TYK2 Quinasa/genética , Tuberculosis/genética , Restos Mortales , Europa (Continente) , Femenino , Genoma Humano/genética , Historia Antigua , Humanos , Masculino , Tuberculosis/historia , Tuberculosis/microbiología
2.
Dev Comp Immunol ; 41(4): 553-63, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23872231

RESUMEN

Tyk2, a member of the Janus Kinase (JAK) family of protein tyrosine kinases, is required for interferon-α/ß binding and signaling in higher vertebrates. Currently, little is known about the role of the different JAKs in signaling responses to interferon (IFN) in lower vertebrates including fish. In this paper we report the identification and characterization of Atlantic salmon (Salmo salar) Tyk2. Four cDNA sequences, two containing an open reading frame encoding full-length Tyk protein and two with an up-stream in frame stop codon, were identified. The deduced amino acid sequences of the salmon full-length Tyk2 proteins showed highest identity with Tyk2 from other species and their transcripts were ubiquitously expressed. Like in mammals the presented data suggests that salmon Tyk2 is auto-phosporylated when ectopically expressed in cells. In our experiments, full-length salmon Tyk2 overexpressed in CHSE-cells phosphorylated itself, while both a kinase-deficient mutant and the truncated Tyk2 (Tyk-short) were inactive. Interestingly, the overexpression of full length Tyk2 was shown to up-regulate the transcript levels of the IFN induced gene Mx, thus indicating the involvement of salmon Tyk2 in the salmon IFN I pathway.


Asunto(s)
Proteínas de Peces/metabolismo , Proteínas Tirosina Quinasas/genética , Proteínas Tirosina Quinasas/metabolismo , Salmo salar/metabolismo , TYK2 Quinasa/metabolismo , Secuencia de Aminoácidos , Animales , Células Cultivadas , Clonación Molecular/métodos , ADN Complementario/genética , Proteínas de Peces/biosíntesis , Proteínas de Peces/genética , Expresión Génica , Interferones/metabolismo , Datos de Secuencia Molecular , Fosforilación , Filogenia , Salmo salar/genética , Homología de Secuencia de Aminoácido , Transducción de Señal , TYK2 Quinasa/biosíntesis , TYK2 Quinasa/genética , Activación Transcripcional
3.
Eur J Nutr ; 51(8): 961-73, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22102159

RESUMEN

PURPOSE: Diabetic glomerulosclerosis is the hardening of the renal glomeruli that can lead to kidney failure. In the early stage of glomerulosclerosis occur renal mesangial expansion and renal filtration dysfunction. Purple corn has been classified as a functional food and is rich in anthocyanins exerting potential disease-preventive activities. The in vitro study using human renal mesangial cells examined that anthocyanin-rich purple corn butanol fraction (PCB) can attenuate high glucose (HG)-promoted mesangial cell proliferation and matrix accumulation. METHODS: Cells were cultured for 3 days in media containing 33 mM glucose in the presence of 1-20 µg/mL PCB. In the in vivo animal study, db/db mice were treated with 10 mg/kg anthocyanin-rich polyphenolic extracts of purple corn (PCE) for 8 weeks. RESULTS: HG enhanced mesangial production of the fibrosis biomarkers of collagen IV and connective tissue growth factor (CTGF), which was markedly attenuated by adding PCB. Such mesangial fibrosis entailed interleukin-8 activation via eliciting Tyk2-STAT signaling pathway. PCB dampened HG-promoted mesangial hyperplasia that appeared to be attributed to increased expression of platelet-derived growth factor. The 8-week administration of PCE lowered plasma glucose level of db/db mice and ameliorated severe albuminuria. Moreover, PCE lessened collagen fiber accumulation in kidney glomeruli and CTGF expression via retarding TGF-ß signaling. Protein expressions of nephrin and podocin, key proteins for filtration barrier function of the glomerular capillary wall, were repressed by treating mice with PCE. CONCLUSION: Purple corn may be a potent therapeutic agent for the treatment for diabetes-associated glomerulosclerosis accompanying proteinuria and kidney filtration dysfunction.


Asunto(s)
Antocianinas/farmacología , Nefropatías Diabéticas/tratamiento farmacológico , Células Mesangiales/efectos de los fármacos , Extractos Vegetales/farmacología , Zea mays/química , Albuminuria/tratamiento farmacológico , Albuminuria/patología , Animales , Biomarcadores/sangre , Glucemia/análisis , Proliferación Celular/efectos de los fármacos , Colágeno Tipo IV/genética , Colágeno Tipo IV/metabolismo , Factor de Crecimiento del Tejido Conjuntivo/genética , Factor de Crecimiento del Tejido Conjuntivo/metabolismo , Nefropatías Diabéticas/complicaciones , Nefropatías Diabéticas/patología , Fibrosis/tratamiento farmacológico , Fibrosis/patología , Humanos , Interleucina-8/metabolismo , Péptidos y Proteínas de Señalización Intracelular/genética , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Masculino , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Células Mesangiales/metabolismo , Ratones , Factor de Crecimiento Derivado de Plaquetas/genética , Factor de Crecimiento Derivado de Plaquetas/metabolismo , Proteinuria/complicaciones , Proteinuria/tratamiento farmacológico , Proteinuria/patología , Factores de Transcripción STAT/genética , Factores de Transcripción STAT/metabolismo , Transducción de Señal , TYK2 Quinasa/genética , TYK2 Quinasa/metabolismo , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/metabolismo
4.
J Immunol ; 187(1): 181-9, 2011 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-21606247

RESUMEN

Tyrosine kinase-2 (Tyk2), a member of the Jak family of kinases, mediates the signals triggered by various cytokines, including type I IFNs, IL-12, and IL-23. In the current study, we investigated the in vivo involvement of Tyk2 in several IL-12/Th1- and IL-23/Th17-mediated models of experimental diseases, including methylated BSA injection-induced footpad thickness, imiquimod-induced psoriasis-like skin inflammation, and dextran sulfate sodium- or 2,4,6-trinitrobenzene sulfonic acid-induced colitis. In these disease models, Tyk2 deficiency influenced the phenotypes in immunity and/or inflammation. Our findings demonstrate a somewhat broader contribution of Tyk2 to immune systems than previously expected and suggest that Tyk2 may represent an important candidate for drug development by targeting both the IL-12/Th1 and IL-23/Th17 axes.


Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Interleucina-12/fisiología , Interleucina-23/fisiología , TYK2 Quinasa/fisiología , Células TH1/enzimología , Células TH1/inmunología , Células Th17/enzimología , Células Th17/inmunología , Adyuvantes Inmunológicos/toxicidad , Aminoquinolinas/toxicidad , Animales , Diferenciación Celular/genética , Colitis/inducido químicamente , Colitis/enzimología , Colitis/inmunología , Sulfato de Dextran/administración & dosificación , Hipersensibilidad Tardía/enzimología , Hipersensibilidad Tardía/inmunología , Imiquimod , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Noqueados , Psoriasis/inducido químicamente , Psoriasis/enzimología , Psoriasis/inmunología , TYK2 Quinasa/deficiencia , TYK2 Quinasa/genética , Células TH1/citología , Células Th17/citología , Ácido Trinitrobencenosulfónico/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA